Invitae And ArcherDX Join Forces To Expand Cancer Genetics And Precision Oncology
Invitae (NYSE: NVTA), a leading genetics and synthetic biology company, and ArcherDX, a leading genomics analysis company innovating in precision oncology, today announced the companies have entered into an agreement to combine. The combined company aims to advance care for cancer patients by accelerating adoption of genetics . Integrating germline testing, tumor profiling and liquid biopsy … Read more